Acurx Pharmaceuticals Inc
ACXP
NASDAQ
Biotechnology
$1.40
USD
-0.09 (-5.74%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.36M
Volume 606.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-7.50M
TTM
+36.9%
YoY
Operating Cash Flow
$-6.14M
TTM
+34.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.6 | 1.7 | 1.6 | 1.3 | 1.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.2 | 2.3 | 2.0 | 1.6 | 1.7 |
Operating Income | -2.2 | -2.3 | -2.0 | -1.6 | -1.7 |
EBITDA | -2.2 | -2.3 | -2.0 | -1.6 | -1.7 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Income Before Income Taxes | -2.1 | -2.2 | -2.0 | -1.6 | -1.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.1 | -2.2 | -2.0 | -1.6 | -1.7 |
Consolidated Net Income / Loss | -2.1 | -2.2 | -2.0 | -1.6 | -1.7 |
Net Income Attributable to Common Shareholders | -2.1 | -2.2 | -2.0 | -1.6 | -1.7 |
Basic EPS | -$2.15 | -$1.89 | -$1.23 | -$0.72 | -$0.62 |
Diluted EPS | -$2.15 | -$1.89 | -$1.23 | -$0.72 | -$0.62 |
Basic Shares Outstanding | 1.0M | 1.2M | 1.6M | 2.2M | 2.7M |
Diluted Shares Outstanding | 1.0M | 1.2M | 1.6M | 2.2M | 2.7M |